Doxanthrine: Difference between revisions

Doxanthrine
Clinical data
ATC code	none;
Identifiers
	IUPAC name (6aS,12bR)-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline-2,3-diol;
PubChem CID	15981509;
ChemSpider	13112900;
CompTox Dashboard (EPA)	DTXSID401028617 ;
Chemical and physical data
Formula	C16H15NO3
Molar mass	269.295 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccc2c(c1)CN[C@H]3[C@H]2c4cc(c(cc4OC3)O)O;
	InChI InChI=1S/C16H15NO3/c18-13-5-11-15(6-14(13)19)20-8-12-16(11)10-4-2-1-3-9(10)7-17-12/h1-6,12,16-19H,7-8H2/t12-,16-/m1/s1; Key:QDUNOUQOKOYLCH-MLGOLLRUSA-N;
	(verify)

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 04:05, 27 August 2017

Doxanthrine is a synthetic compound which is a potent and selective full agonist for the dopamine D₁ receptor.^[1]^[2] Doxanthrine has been shown to be orally active in producing contralateral rotation in the 6-hydroxy-dopamine rat model of Parkinson's disease.^[3]

References

^ Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE (November 2006). "trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist". Journal of Medicinal Chemistry. 49 (23): 6848–57. doi:10.1021/jm0604979. PMID 17154515.
^ Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ (February 2009). "Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 19 (2): 138–46. doi:10.1016/j.euroneuro.2008.10.002. PMC 2636714. PMID 19028082.
^ McCorvey JD, Watts VJ, Nichols DE (July 2012). "Comparison of the D1 dopamine full agonists,dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease". Psychopharmacology. 222 (1): 81–87. doi:10.1007/s00213-011-2625-5. PMID 22222862.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[pmid17154515-1] Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE (November 2006). "trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist". Journal of Medicinal Chemistry. 49 (23): 6848–57. doi:10.1021/jm0604979. PMID 17154515.

[pmid19028082-2] Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ (February 2009). "Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 19 (2): 138–46. doi:10.1016/j.euroneuro.2008.10.002. PMC 2636714. PMID 19028082.

[3] McCorvey JD, Watts VJ, Nichols DE (July 2012). "Comparison of the D1 dopamine full agonists,dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease". Psychopharmacology. 222 (1): 81–87. doi:10.1007/s00213-011-2625-5. PMID 22222862.

[1]

[2]

[3]

@@ Line 31: / Line 31: @@
 }}
-'''Doxanthrine''' is a [[synthetic compound]] which is a [[potency (pharmacology)|potent]] and [[binding selectivity|selective]] [[full agonist]] for the [[dopamine]] [[D1 receptor|D<sub>1</sub> receptor]].<ref name="pmid17154515">{{cite journal |vauthors=Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE |title=trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist |journal=Journal of Medicinal Chemistry |volume=49 |issue=23 |pages=6848–57 |date=November 2006 |pmid=17154515 |doi=10.1021/jm0604979 |url=}}</ref><ref name="pmid19028082">{{cite journal |vauthors=Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ |title=Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors |journal=European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology |volume=19 |issue=2 |pages=138–46 |date=February 2009 |pmid=19028082 |doi=10.1016/j.euroneuro.2008.10.002 |url= |pmc=2636714}}</ref> Doxanthrine has been shown to be orally active in producing contralateral rotation in the 6-hydroxy-dopamine rat model of Parkinson's disease.<ref>{{cite journal |vauthors=McCorvey JD, Watts VJ, Nichols DE |date=July 2012 |title= Comparison of the D1 dopamine full agonists,dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease |journal=Psychopharmacology (Berl) |publisher= |volume=222 |pages=81–87 |doi=10.1007/s00213-011-2625-5 |pmid=22222862 |issue=1}}</ref>
+'''Doxanthrine''' is a [[synthetic compound]] which is a [[potency (pharmacology)|potent]] and [[binding selectivity|selective]] [[full agonist]] for the [[dopamine]] [[D1 receptor|D<sub>1</sub> receptor]].<ref name="pmid17154515">{{cite journal |vauthors=Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE |title=trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist |journal=Journal of Medicinal Chemistry |volume=49 |issue=23 |pages=6848–57 |date=November 2006 |pmid=17154515 |doi=10.1021/jm0604979 |url=}}</ref><ref name="pmid19028082">{{cite journal |vauthors=Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ |title=Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors |journal=European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology |volume=19 |issue=2 |pages=138–46 |date=February 2009 |pmid=19028082 |doi=10.1016/j.euroneuro.2008.10.002 |url= |pmc=2636714}}</ref> Doxanthrine has been shown to be orally active in producing contralateral rotation in the 6-hydroxy-dopamine rat model of Parkinson's disease.<ref>{{cite journal |vauthors=McCorvey JD, Watts VJ, Nichols DE |date=July 2012 |title= Comparison of the D1 dopamine full agonists,dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease |journal=Psychopharmacology |publisher= |volume=222 |pages=81–87 |doi=10.1007/s00213-011-2625-5 |pmid=22222862 |issue=1}}</ref>
 == References ==